Myth-buster
Platelet count trajectory predicted sepsis mortality (HR 0.97 per 10^9/L rise), but vitamin C had no effect on that link — null result from 863-patient trial.
This post-hoc analysis of the LOVIT trial contradicts the hope that high-dose vitamin C could reduce sepsis mortality through platelet effects, and adds to a body of evidence (1 beneficial, 4 neutral) showing no clear benefit.
Researchers analyzed data from 863 sepsis patients to see if vitamin C's lack of effect on mortality might be explained by platelet count changes. While rising platelet levels over four days were linked to lower death risk (28% lower per 10 billion/L increase), vitamin C did not alter that trajectory or improve survival. This null result, from a post-hoc analysis of a trial that already found no overall benefit, reinforces that vitamin C does not reduce mortality in sepsis — despite its anti-inflammatory reputation.
Where this fits in the evidence
Pillser has synthesized 5 studies on Vitamin C for Reduced Mortality Risk — overall evidence strength: Low.
Across 5 studies, 1 reported a beneficial moderate-sized effect of Vitamin C on reducing mortality risk in COVID-19 patients, while 4 studies found neutral small effects, primarily in sepsis populations. The median study duration was only 4 days (from 1 study reporting duration), which is too short to assess long-term mortality outcomes. Most evidence comes from clinical populations with acute critical illness.
The study
- Randomized Controlled Trial (RCT)
- n = 863
- 2025-09
- Critical care explorations
This is a plain-language summary of a research finding, not medical advice. Pillser surfaces research signals to help you decide what's worth investigating — always consult a qualified professional before changing what you take.